Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15464069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.

  2003cited by this paper
• Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats

  2003cited by this paper
• κ Opioid Receptor Antagonism and Prodynorphin Gene Disruption Block Stress-Induced Behavioral Responses

  2003cited by this paper
• The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole.

  2003cited by this paper
• Naloxone treatment for irritable bowel syndrome — a randomized controlled trial with an oral formulation

  2002cited by this paper
• Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys

  2002cited by this paper
• Pharmacotherapy of addictions

  2002cited by this paper
• Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation.

  2002cited by this paper
• The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats.

  2001cited by this paper
• Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.

  2001cited by this paper
• Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.

  2000cited by this paper
• 5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist.

  2000cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000cited by this paper
• An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

  2000cited by this paper
• U-50,488 and the kappa receptor. Part II: 1991-1998.

  1999cited by this paper
• Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.

  1998cited by this paper
• Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.

  1998cited by this paper
• Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.

  1998cited by this paper
• Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity.

  1997cited by this paper
• Buprenorphine treatment of refractory depression.

  1995cited by this paper
• Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders.

  1994cited by this paper
• 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

  1993cited by this paper
• Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.

  1993cited by this paper
• Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo.

  1992cited by this paper
• Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.

  1992cited by this paper
• kappa-Opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury.

  1991cited by this paper
• Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents.

  1990cited by this paper
• Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey.

  1988cited by this paper
• Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.

  1988cited by this paper
• Bimorphinans as highly selective, potent kappa opioid receptor antagonists.

  1987cited by this paper
• Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

  1987cited by this paper
• Effects of buprenorphine on shock titration in squirrel monkeys.

  1985cited by this paper
• Further study of kappa opioids on increased urination.

  1983cited by this paper
• A kappa opioid effect: increased urination in the rat.

  1983cited by this paper
• Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

  1982cited by this paper
• Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

  1982cited by this paper
• The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests.

  1970cited by this paper

• Co-targeting the kappa opioid receptor and dopamine transporter reduces motivation to self-administer cocaine and partially reverses dopamine system dysregulation

  2024cites this paper
• Naltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane

  2024cites this paper
• LY2444296, a κ-opioid receptor antagonist, selectively reduces alcohol drinking in male and female Wistar rats with a history of alcohol dependence

  2024cites this paper
• A review of kappa opioid receptor antagonists and their clinical trial landscape.

  2024cites this paper
• Stress‐related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective

  2023cites this paper
• Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance.

  2022cites this paper
• A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse.

  2022cites this paper
• Contributions of the International Narcotics Research Conference to Opioid Research Over the Past 50 years

  2022cites this paper
• The role of kappa opioid receptors in immune system - An overview.

  2022cites this paper
• Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes

  2021cites this paper
• Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands.

  2021cites this paper
• Kappa Opioid Agonist-Induced Diuresis: Characteristics, Mechanisms, and Beyond.

  2021cites this paper
• Neurobiology of alcohol seeking behavior

  2021cites this paper
• Structural Characterization of KOR Inactive and Active States for 3D Pharmacology and Drug Discovery.

  2021cites this paper
• Deciphering the molecular basis of the kappa opioid receptor selectivity: A Molecular Dynamics study.

  2021cites this paper
• Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat

  2020cites this paper
• Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action

  2020cites this paper
• Frontal Cortical Monoamine Release, Attention, and Working Memory in a Perinatal Nicotine Exposure Mouse Model Following Kappa Opioid Receptor Antagonism.

  2020cites this paper
• Contributions of µ- and κ-opioidergic systems to ethanol intake and addiction

  2019influential citation
• The selective κ-opioid receptor antagonist JDTic attenuates the alcohol deprivation effect in rats.

  2019cites this paper
• Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats

  2019cites this paper
• Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).

  2018cites this paper
• Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging.

  2018cites this paper
• Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

  2018cites this paper
• Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

  2018cites this paper
• Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?

  2018cites this paper
• Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders

  2018influential citation
• The κ-opioid receptor antagonist JDTic decreases ethanol intake in alcohol-preferring AA rats

  2018influential citation
• N-[18F]-FluoropropylJDTic for κ-opioid receptor PET imaging: Radiosynthesis, pre-clinical evaluation, and metabolic investigation in comparison with parent JDTic.

  2017cites this paper
• “Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”

  2017cites this paper
• Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.

  2017cites this paper
• Effects of Chronic Social Defeat Stress on Sleep and Circadian Rhythms Are Mitigated by Kappa-Opioid Receptor Antagonism

  2017cites this paper
• Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.

  2017cites this paper
• Opioid Receptor Modulators with a Cinnamyl Group.

  2017cites this paper
• Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.

  2017cites this paper
• Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats

  2017cites this paper
• In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential

  2017cites this paper
• Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.

  2016cites this paper
• Sustained Suppression of Hyperalgesia during Latent Sensitization by μ-, δ-, and κ-opioid receptors and α2A Adrenergic Receptors: Role of Constitutive Activity

  2016influential citation
• Does the combination of buprenorphine/naltrexone have antidepressant efficacy in animal models?

  2016cites this paper
• The Role of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in the Neurobiology of Stress-Related Behaviors

  2016cites this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP) disrupts motivation, social interaction, and attention in male Sprague-Dawley rats

  2016cites this paper
• Pituitary Adenylate Cyclase–Activating Polypeptide Disrupts Motivation, Social Interaction, and Attention in Male Sprague Dawley Rats

  2016cites this paper
• Major Depressive Disorder and Kappa Opioid Receptor Antagonists

  2016cites this paper
• Dynorphin A analogs for the treatment of chronic neuropathic pain.

  2016cites this paper
• Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.

  2016influential citation
• nor-BNI Antagonism of Kappa Opioid Agonist-Induced Reinstatement of Ethanol-Seeking Behavior

  2016cites this paper
• Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.

  2016cites this paper
• THIS IS THE FINAL DRAFT POST-REFEREEING AND IS ALLOWED TO BE MADE AVAILABLE, WHERE THE HOST INSTITUTION MANDATES IT, AFTER 12 MONTHS EMBARGO

  2015cites this paper
• Microsoft Word-80048204-file00.docx

  2015cites this paper
• BU08073 a buprenorphine analogue with partial agonist activity at μ‐receptors in vitro but long‐lasting opioid antagonist activity in vivo in mice

  2015cites this paper
• IS THE FINAL DRAFT POST-REFEREEING AND IS ALLOWED TO BE MADE AVAILABLE , WHERE THE HOST INSTITUTION MANDATES IT , AFTER 12 MONTHS EMBARGO

  2015cites this paper
• A Novel Method for Analyzing Extremely Biased Agonism at G Protein–Coupled Receptors

  2015cites this paper
• Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.

  2015cites this paper
• Targeting Itch with Ligands Selective for κ Opioid Receptors.

  2015cites this paper
• Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice

  2015influential citation
• Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system

  2015cites this paper
• Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.

  2015cites this paper
• Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.

  2015cites this paper
• Discovery of the First Small-Molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa, and Nociceptin Opioid Receptors

  2015cites this paper
• Kappa-opioid receptor antagonism: a mechanism for treatment of relief drinking?

  2014cites this paper
• Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening.

  2014cites this paper
• The Discovery and Development of the N‐Substituted trans‐3,4‐Dimethyl‐4‐(3′‐hydroxyphenyl)piperidine Class of Pure Opioid Receptor Antagonists

  2014cites this paper
• Elucidation of Conformational States, Dynamics, and Mechanism of Binding in Human κ-Opioid Receptor Complexes

  2014cites this paper
• Diastereoselective syntheses of (3R*,4R*)- and (3R*,4S*)-4-aryl-3-methyl-4-piperidinemethanol and fluoro analogues.

  2013cites this paper
• Dynorphin–Still an Extraordinarily Potent Opioid Peptide

  2013cites this paper
• Synthesis and biological evaluation of dynorphin analogs and, Caco-2 permeability of opioid macrocyclic tetrapeptides

  2013cites this paper
• Kappa-Opioid Receptor Signaling in the Striatum as a Potential Modulator of Dopamine Transmission in Cocaine Dependence

  2013cites this paper
• Development of κ opioid receptor antagonists.

  2013cites this paper
• The macrocyclic tetrapeptide [D‐Trp]CJ‐15,208 produces short‐acting κ opioid receptor antagonism in the CNS after oral administration

  2013cites this paper
• ISSUE IN MEMORY OF AVRAM GOLDSTEIN Dynorphin – Still an Extraordinarily Potent Opioid Peptide

  2013influential citation
• Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.

  2013cites this paper
• Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity

  2012influential citation
• Structure of the human kappa opioid receptor in complex with JDTic

  2012cites this paper
• Ligand‐directed signalling within the opioid receptor family

  2012cites this paper
• Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.

  2012cites this paper
• The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) rats.

  2012cites this paper
• Molecular profiling of activated neurons by phosphorylated ribosome capture.

  2012cites this paper
• Corticotropin-Releasing Factor (CRF)-Induced Disruption of Attention in Rats Is Blocked by the κ-Opioid Receptor Antagonist JDTic

  2012influential citation
• The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety

  2012influential citation
• Buprenorphine and Opioid Antagonism, Tolerance, and Naltrexone-Precipitated Withdrawal

  2011cites this paper
• Deletion of Ac‐NMePhe1 from [NMePhe1]arodyn under acidic conditions, part 2: Effects of substitutions on pharmacological activity

  2011cites this paper
• Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation

  2011cites this paper
• Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity.

  2011cites this paper
• Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats.

  2011cites this paper
• Kinase cascades and ligand-directed signaling at the kappa opioid receptor

  2010influential citation
• Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement

  2010cites this paper
• Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse

  2010cites this paper
• Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.

  2010cites this paper
• Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents

  2010cites this paper
• Applications and modifications of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in peptides and peptidomimetics design and discovery.

  2010cites this paper
• Dynorphin, stress, and depression.

  2010cites this paper
• 1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists.

  2010cites this paper
• Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

  2009cites this paper
• Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.

  2009cites this paper
• Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

  2009cites this paper
• Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

  2009cites this paper
• Antidepressant-Like Effects of the Novel Kappa Opioid Antagonist MCL-144B in the Forced-Swim Test

  2008cites this paper
• [11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging.

  2008cites this paper
• Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

  2008cites this paper